European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

October 30th 2020


  • EIB support to develop breakthrough treatments to address orphan neurodegenerative diseases with high unmet medical needs
  • Focus on Minoryx’s lead asset, leriglitazone, a novel, disease-modifying PPAR-γ agonist
  • Venture debt operation supported by the Investment Plan for Europe

Please discover the press release here.​